Layne Sadler - KeyBio

<p class="p1"><span class="s1">Angel Scale Biotech: <a href= "https://syndicate.angelinvestboston.com/en-us/the-surge-of-opportunities-in-angel-scale-biotech"> Learn More</a></span></p> <p class="p1"> </p> <p class="p1"><span class="s1">Layne Sadler founded KeyBio to help pharmaceutical companies better identify genetic traits in patients that may explain differing responses to cancer treatments. KeyBio’s computational approach promises to add a new dimension to precision medicine, which now looks at the genetics of the tumor, by also incorporating the genetics of the patient to improve outcomes in clinical trials.</span></p> <p class="p2"> </p> <p class="p2">Sponsored by Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson.</p> <p class="p2"> </p> <p class="p1"><span class="s1">Highlights:</span></p> <ul class="ul1"> <li class="li3"><span class="s1">Sal Daher Introduces Layne Sadler</span></li> <li class="li3"><span class="s1">What KeyBio is Solving</span></li> <li class="li3"><span class="s1">"... The revenue is solely focused on cancer drug discovery and the reason for that is because that's where all the money is in the pharmaceutical industry..."</span></li> <li class="li3"><span class="s1">"... 90% of clinical trials fail and the cost averages around 792 million, spending about a billion dollars to run a trial..."</span></li> <li class="li3"><span class="s1">"... I developed this AI platform and I wanted to start collaborating with other principal investigators or heads of labs in the Boston area..."</span></li> <li class="li3"><span class="s1">"... The DNA of tumors, over time, it mutates and it becomes very different from the DNA of the host..."</span></li> <li class="li3"><span class="s1">Why Layne Chose Entrepreneurship</span></li> </ul> <p class="p2"> </p> <p class="p1"><span class="s1">Topics: biotech, founding story, discovering entrepreneurship</span></p>